Sorrento Announces FDA Authorization to Proceed With Phase II Study of Abivertinib (Fujovee^™) to Treat Metastatic Castrate Resistant Prostate Cancer (MAVERICK Trial)

Sorrento Therapeutics, Inc. announced that it has received clearance from the FDA for its investigational new drug application for Abivertinib or the Phase II MAVERICK study to be conducted in participants with metastatic CRPC at multiple centers in the United States.